We are live on ! Find out more
PRAX icon

Praxis Precision Medicines

152 hedge funds and large institutions have $1.31B invested in Praxis Precision Medicines in 2025 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 59 increasing their positions, 45 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 19

31% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 45

29% more capital invested

Capital invested by funds: $1.02B → $1.31B (+$292M)

20% more call options, than puts

Call options by funds: $27.3M | Put options by funds: $22.7M

6% more funds holding

Funds holding: 143152 (+9)

1.39% less ownership

Funds ownership: 118.57%117.18% (-1.4%)

50% less funds holding in top 10

Funds holding in top 10: 63 (-3)

Holders
152
Holders Change
+9
Holders Change %
+6.29%
% of All Funds
1.99%
Holding in Top 10
3
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
28
Increased
59
Reduced
45
Closed
19
Calls
$27.3M
Puts
$22.7M
Net Calls
+$4.62M
Net Calls Change
-$6.17M
Name Holding Trade Value Shares
Change
Change in
Stake
Charles Schwab
26
Charles Schwab
California
$8.57M +$447K +9,217 +6%
AG
27
Algert Global
California
$8.52M +$6.46M +133,248 +483%
Alyeska Investment Group
28
Alyeska Investment Group
Illinois
$7.5M +$801K +16,516 +13%
VCIM
29
Velan Capital Investment Management
Georgia
$7.04M -$801K -16,529 -11%
LGM
30
Logos Global Management
California
$6.63M -$4.85M -100,000 -44%
RAM
31
Readystate Asset Management
Illinois
$5.79M +$5.29M +109,177 New
EAM
32
Exome Asset Management
New York
$5.41M +$2.08M +42,994 +73%
UBS Group
33
UBS Group
Switzerland
$5.13M +$498K +10,278 +12%
HS
34
HighVista Strategies
Massachusetts
$5.04M +$1.34M +27,714 +41%
Barclays
35
Barclays
United Kingdom
$4.06M -$586K -12,087 -14%
KCM
36
Kennedy Capital Management
Missouri
$4.04M +$280K +5,773 +8%
TLP
37
Tri Locum Partners
New York
$4.03M -$5.79M -119,446 -61%
Marshall Wace
38
Marshall Wace
United Kingdom
$3.61M +$3.3M +68,141 New
7IH
39
72 Investment Holdings
Connecticut
$3.49M
CS
40
Candriam SCA
Luxembourg
$3.33M -$39K -805 -1%
Wellington Management Group
41
Wellington Management Group
Massachusetts
$3.25M +$260K +5,360 +10%
PHS
42
PFM Health Sciences
California
$3.21M -$1.17M -24,135 -28%
SFM
43
Sphera Funds Management
Israel
$3.07M -$2.51M -51,856 -47%
Qube Research & Technologies (QRT)
44
Qube Research & Technologies (QRT)
United Kingdom
$3.04M +$2.78M +57,304 New
Bank of New York Mellon
45
Bank of New York Mellon
New York
$2.98M +$181K +3,735 +7%
SCM
46
Silverarc Capital Management
Massachusetts
$2.71M +$2M +41,210 +412%
ACP
47
Acuta Capital Partners
California
$2.64M -$1.18M -24,336 -33%
Fidelity Investments
48
Fidelity Investments
Massachusetts
$2.29M +$248K +5,111 +13%
TD Asset Management
49
TD Asset Management
Ontario, Canada
$2.17M -$1.12M -23,054 -36%
BFM
50
Boothbay Fund Management
New York
$2.1M -$3.8M -78,461 -66%

PRAX Hedge Fund Activity: Q3 2025 in Review

152 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q3 2025, worth a combined $1.31B — up 29% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new PRAX positions and 19 closed out — a net gain of 9 holders — while 59 added to existing stakes and 45 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $39.4M. The largest seller was Cormorant Asset Management, cutting an estimated $30.3M.

  • 152 institutional investors held Praxis Precision Medicines (PRAX) as of Q3 2025, up from 143 in Q2 2025.
  • Funds reported $1.31B of Praxis Precision Medicines stock for Q3 2025, up 29% quarter-over-quarter.
  • 28 funds opened new Praxis Precision Medicines positions in Q3 2025 and 19 closed out, a net change of +9 holders.
  • The largest Praxis Precision Medicines buyer in Q3 2025 was Perceptive Advisors, an estimated $39.4M added.
  • The largest Praxis Precision Medicines seller in Q3 2025 was Cormorant Asset Management, an estimated $30.3M sold.

Based on aggregated 13F filings for Q3 2025.